Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 15/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | ASPH | Q12797 | 2/20 | 0.39 |
| ▸ | RIOX2 | Q8IUF8 | 2/20 | 0.39 |
| ▸ | KDM8 | Q8N371 | 2/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30765980 | 0.90 | ELANE (0.39) | ELANEKDM4EASPHRIOX2KDM8 | |
| SCHEMBL30766097 | 0.84 | ASPH (0.49) | ELANEKDM4EASPHRIOX2KDM8 | |
| SCHEMBL30766006 | 0.81 | KDM4E (0.42) | ELANEKDM4EASPHRIOX2KDM8 | |
| SCHEMBL30765706 | 0.79 | ELANE (0.47) | ELANEKDM4EEGLN1 | |
| SCHEMBL23461187 | 0.78 | KDM4E (0.47) | ELANEKDM4EASPHRIOX2KDM8 | |
| SCHEMBL30766118 | 0.78 | ELANE (0.41) | ELANEKDM4EASPHRIOX2KDM8 | |
| SCHEMBL30765490 | 0.78 | ELANE (0.39) | ELANEKDM4EASPHRIOX2KDM8 | |
| SCHEMBL30765659 | 0.76 | ELANE (0.39) | ELANEKDM4EASPHRIOX2KDM8 | |
| SCHEMBL30765994 | 0.76 | ELANE (0.46) | ELANEKDM4EASPHRIOX2KDM8 | |
| SCHEMBL30765905 | 0.76 | ELANE (0.39) | ELANEKDM4EASPHRIOX2KDM8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4568666-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | Alexion Pharmaceuticals, Inc. (US) | 2025-06-18 | — | — | EP | disclosed |
| WO-2024035686-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2024-02-15 | — | — | WO | disclosed |